Tamoxifen-related vasculitis.
Baptista
Mauricio Z
MZ
Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Prieto
Victor G
VG
Chon
Susan
S
Hortobagyi
Gabriel N
GN
Esteva
Francisco J
FJ
D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D001943:Breast Neoplasms / Q000473:pathology* / Q000628:therapy; D020847:Estrogen Receptor Modulators / Q000009:adverse effects; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D012867:Skin / Q000098:blood supply / Q000187:drug effects*; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects*; D014657:Vasculitis / Q000139:chemically induced* / Q000473:pathology
D018931:Antineoplastic Agents, Hormonal; D050071:Bone Density Conservation Agents; D020847:Estrogen Receptor Modulators; D013629:Tamoxifen